<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Stock Blog Hub &#187; Novo Nordisk A/s</title>
	<atom:link href="http://www.stockbloghub.com/tag/novo-nordisk-as/feed" rel="self" type="application/rss+xml" />
	<link>http://www.stockbloghub.com</link>
	<description>Start Your Investing Research Here!</description>
	<lastBuildDate>Wed, 23 May 2012 20:22:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.3.2</generator>
		<item>
		<title>(NVO) Novo Nordisk AS &#8211; 5 analysts raised projections in the past month</title>
		<link>http://www.stockbloghub.com/2009/07/24/novo-nordisk/11235</link>
		<comments>http://www.stockbloghub.com/2009/07/24/novo-nordisk/11235#comments</comments>
		<pubDate>Fri, 24 Jul 2009 18:32:04 +0000</pubDate>
		<dc:creator>Shawn</dc:creator>
				<category><![CDATA[Drug Manufacturers - Other]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[Novo Nordisk A/s]]></category>
		<category><![CDATA[NVO]]></category>

		<guid isPermaLink="false">http://www.stockbloghub.com/?p=11235</guid>
		<description><![CDATA[Novo Nordisk (NVO) shares are climbing on estimate revisions as the next report approaches. Company Description Novo manufactures pharmaceutical products and specializes in insulin and diabetes care. The biopharmaceutical segment explores hormone therapy and homeostasis management. Estimates Up Analysts are raising estimates as the next quarterly report nears. The consensus estimate for this year is now $3.17, up from $3.01 over the past 3 months. Estimates for next year are averaging $3.77, up from $3.65 in that time span. These forecasts represent year-over-year earnings growth of 4% and 19%, respectively, as all 5 analysts raised projections in the past month. Strong Quarterly Results Novo reported its first-quarter results in April, which included an 18% jump in sales. Profits rose 35% on a year-over-year basis. Industry Comparisons One of the most ]]></description>
		<wfw:commentRss>http://www.stockbloghub.com/2009/07/24/novo-nordisk/11235/feed</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>

